Aligos Therapeutics Updates Progress on B-SUPREME Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Aligos Therapeutics announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus, HBV, infection. The first protocol defined interim analysis includes approximately 60% HBeAg- participants that complete 12 weeks of the treatment period. This enrollment milestone occurred in Q4 2025. In addition, the planned enrollment of this cohort of 60 HBeAg- participants completed in January 2026. The first interim analysis is expected to occur in the first half of 2026. A second protocol defined interim analysis is planned when approximately 50% HBeAg+ participants complete 24 weeks of the treatment period. This enrollment milestone occurred in January 2026. This interim analysis is expected to occur in the second half of 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALGS
Wall Street analysts forecast ALGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGS is 81.67 USD with a low forecast of 20.00 USD and a high forecast of 175.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.590
Low
20.00
Averages
81.67
High
175.00
Current: 8.590
Low
20.00
Averages
81.67
High
175.00
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Onco3R Appoints Lawrence Blatt as Board Chair to Drive Growth
- Leadership Change: Onco3R Therapeutics announced the appointment of Dr. Lawrence M. Blatt as Chair of the Board, bringing extensive drug development and strategic leadership experience to guide the company's next growth phase.
- Industry Expertise: Blatt has served as CEO of Aligos Therapeutics since 2018 and previously led global infectious diseases and vaccines at Janssen Pharmaceuticals, providing a strong industry background.
- Product Development Potential: Onco3R's O3R-5671, designed for autoimmune diseases based on over 12 years of preclinical and clinical data, shows promising safety and efficacy, with potential applications in various autoimmune conditions.
- Clinical Trial Plans: The Phase 1 trial for O3R-5671 is set to commence in 2026, assessing safety and pharmacokinetics while utilizing biomarker tests to gain insights into its immune modulation mechanisms.
Continue Reading
Aligos Grants 14,100 Stock Options to New Employees Under Inducement Plan
- Stock Option Grant: Aligos Therapeutics granted a total of 14,100 non-qualified stock options to new employees on December 9, 2025, aimed at attracting top talent and enhancing employee loyalty, in compliance with Nasdaq listing rules.
- Incentive Plan Implementation: The stock options were granted under Aligos' 2024 Inducement Plan, ensuring that new hires benefit from equity incentives during their tenure, thereby improving overall team stability and execution.
- Exercise Price Setting: The exercise price of the stock options is set at the closing price on the grant date, ensuring that new employees can share in the value growth of the company, further motivating them to contribute to its development.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, a structure that not only helps retain talent but also aligns employee goals with the company's objectives.
Continue Reading